What is the container volume for the 15A model?

The container volume for the FL 15A model is 45 liters.

What is the maximum granulation capacity?

The maximum capacity for the 15A model is 20 kg/h.

What certifications does the machine have?

The machine is certified with CE, GMP, and ISO standards.

Fl 15A Fluidized Granulator for Pharmaceuticals

Name: Fl 15A Fluidized Granulator for Pharmaceuticals
Brand: Shanghai Pharmaceutical Machinery Co., Ltd.
SKU: 766900065

Shanghai, ChinaShanghai Pharmaceutical Machinery Co., Ltd.

US$1.00-20,000.00

1 Set

Product profile

Certification

CE, GMP, ISO

Container Volume

45L

Container Diameter

550mm

Model NO.

FL 15A

Capability Min

10kg/H

Capability Max

20kg/H

Fan Capacity

1400 M3/H

Type

Preparation Machinery

Finished Dosage Form

Granules

Precision

High Precision

Computerized

Customized

Non-Customized

Condition

New

Warranty

1 Year

Voltage

According to Your Requirement

Transport Package

Seaworthy

Specification

GMP

Trademark

SPM

Origin

Shanghai

HS Code

8479899990

Production Capacity

10~20kg/H

Key features

GMP Compliance: Designed to meet strict GMP requirements for pharmaceutical production.

One-Step Process: Mixing, granulating, and drying completed in a single machine step.

Safety Features: Includes antistatic filtering cloth and explosion releasing holes.

No Dead Corners: Clean design ensures quick and easy loading and unloading.

Versatile Application: Suitable for pharmaceuticals, food, pesticides, and chemical industries.

Company profile

Experienced TeamExhibition ExperienceImporters and ExportersLow MOQ

Shanghai Pharmaceutical Machinery Co., Ltd.

Shanghai, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 20 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤6.18h CertifiedTerms of Payment: T/T, LC, PayPal, etc.

AI-Powered supplier vetting

SummaryThe supplier is identified as a Shanghai-based combined trading company with listed pharmaceutical equipment products and machining-related facilities. It reports extensive customization, R&D activity with new products in the past year, export experience of 20 years, and exports representing 90% of total sales. After-sales support includes repair services and overseas agents or branches, but no overseas warehouse or showroom. Finished-product inspection instructions are reportedly available and uniformly followed. The supplier does not provide ODM services, lacks an available SDK, and does not provide OEM services for well-known brands. Evidence is insufficient to verify certifications, detailed financial credibility, production scale, or named customer cases.

After-Sales capabilityThe supplier reports repair as an overseas service offering and states that it can provide services through overseas agents or branches. However, it has no overseas warehouse or showroom, so the evidence supports some service access but not comprehensive overseas infrastructure.

R&D capabilityThe supplier reports R&D capability and states that it launched new products during the past year. It does not have an available SDK and does not provide ODM services, but these limitations do not negate the explicit evidence of recent product development.

Production capacityThe supplier lists machining centers, CNC and milling equipment, provides a broad pharmaceutical-equipment product range, and reports a finished-product inspection method with instructions that are uniformly followed. However, the supplied data does not quantify production capacity, output, or manufacturing ownership, so production strength is only partially evidenced.

Customization capabilityBoth R&D and design-service records explicitly list customization from samples, designs, full customization, minor customization, and flexible customization. This is direct evidence of a broad customization offering.